416 related articles for article (PubMed ID: 27856656)
1. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis.
Tanaka Y
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii15-ii22. PubMed ID: 27856656
[TBL] [Abstract][Full Text] [Related]
2. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
Tanaka Y; Hirata S
Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
[TBL] [Abstract][Full Text] [Related]
3. Current concepts in the management of rheumatoid arthritis.
Tanaka Y
Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
[TBL] [Abstract][Full Text] [Related]
4. Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis.
Tanaka Y; Hirata S
Drugs; 2014 Dec; 74(18):2129-39. PubMed ID: 25389048
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
[TBL] [Abstract][Full Text] [Related]
6. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
7. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
[TBL] [Abstract][Full Text] [Related]
8. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis.
Tanaka Y
Curr Opin Rheumatol; 2012 May; 24(3):319-26. PubMed ID: 22388646
[TBL] [Abstract][Full Text] [Related]
9. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
Naniwa T; Iwagaitsu S; Kajiura M
Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
[TBL] [Abstract][Full Text] [Related]
11. Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study.
Juhász P; Mester A; Biró AJ; Héjj G; Poór G
BMC Musculoskelet Disord; 2014 Jul; 15():251. PubMed ID: 25059769
[TBL] [Abstract][Full Text] [Related]
12. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
Smolen JS; Pedersen R; Jones H; Mahgoub E; Marshall L
Rheumatology (Oxford); 2020 Jan; 59(1):153-164. PubMed ID: 31257453
[TBL] [Abstract][Full Text] [Related]
13. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
[TBL] [Abstract][Full Text] [Related]
17. Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.
Koike T
J Orthop Sci; 2015 Nov; 20(6):951-7. PubMed ID: 26404390
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
[TBL] [Abstract][Full Text] [Related]
19. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
Finckh A; Dehler S; Gabay C;
Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
